Luận án Biểu hiện PD-L1, đặc điểm lâm sàng và giải phẫu bệnh trong đáp ứng xạ trị và tiên lượng ung thư hốc miệng

26. Rivera C, Oliveira AK, Costa RAP, et al. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. Oral Oncol. Sep 2017;72:38-47. doi:10.1016/j.oraloncology.2017.07.003 27. Kamran SC, Berrington de Gonzalez A, Ng A, et al. Therapeutic radiation and the potential risk of second malignancies. Cancer. Jun 15 2016;122(12):1809-21. doi:10.1002/cncr.29841 28. Mitsudo K, Tohnai I. Cemoradiotherapy using intra-arterial infusion. Oral Cancer: Diagnosis and Therapy. Kirita T., Omura K. Eds. Springer-Japan, Tokyo; 2015. 29. Bahadur S, Iyer S. Management of Oral Cancers. Springer; 2021. 30. Lin LH, Chang KW, Kao SY, et al. Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer. Int J Mol Sci. Oct 24 2018;19(11)doi:10.3390/ijms19113303 31. Morikawa T, Shibahara T, Nomura T, et al. Non-Invasive Early Detection of Oral Cancers Using Fluorescence Visualization with Optical Instruments. Cancers (Basel). Sep 27 2020;12(10)doi:10.3390/cancers12102771 32. Cao LM, Zhong NN, Li ZZ, et al. Lymph node metastasis in oral squamous cell carcinoma: Where we are and where we are going. Clinical and Translational Discovery. 2023;3(4):e227. 33. El-Naggar AK, Chan JKC, Takata T, et al. The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. Hum Pathol. Aug 2017;66:10-12. doi:10.1016/j.humpath.2017.05.014 34. Akhter M, Hossain S, Rahman QB, et al. A study on histological grading of oral squamous cell carcinoma and its co-relationship with regional metastasis. J Oral Maxillofac Pathol. May 2011;15(2):168-76. doi:10.4103/0973-029X.84485 35. Rahadiani N, Habiburrahman M, Handjari DR, et al. Clinicopathological characteristics predicting advanced stage and surgical margin invasion of oral squamous cell carcinoma: A single-center study on 10 years of cancer registry data. Oncol Lett. Oct 2022;24(4):364. doi:10.3892/ol.2022.13484 36. Wunschel M, Neumeier M, Utpatel K, et al. Staging more important than grading? Evaluation of malignancy grading, depth of invasion, and resection margins in oral squamous cell carcinoma. Clin Oral Investig. Mar 2021;25(3):1169-1182. doi:10.1007/s00784-020-03421-2 37. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. Jun 1987;95(3):229-49. doi:10.1111/j.1600-0722.1987.tb01836.x 38. Bryne M, Koppang HS, Lilleng R, et al. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol. Apr 1992;166(4):375-81. doi:10.1002/path.1711660409 39. Moeckelmann N, Ebrahimi A, Tou YK, et al. Prognostic implications of the 8th edition American Joint Committee on Cancer (AJCC) staging system in oral cavity squamous cell carcinoma. Oral Oncol. Oct 2018;85:82-86. doi:10.1016/j.oraloncology.2018.08.013 40. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. Mar 2017;67(2):122-137. doi:10.3322/caac.21389 41. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. Mar 2017;67(2):93-99. doi:10.3322/caac.21388 42. Schulz A, Meyer F, Dubrovska A, et al. Cancer Stem Cells and Radioresistance: DNA Repair and Beyond. Cancers (Basel). Jun 21 2019;11(6)doi:10.3390/cancers11060862 43. Nguyễn Thái Hà, Nguyễn Đức Thuần. Y học hạt nhân và kỹ thuật xạ trị. NXB Bách khoa Hà Nội; 2006. 44. Baumann R, Depping R, Delaperriere M, et al. Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale? Expert review of anticancer therapy. Jul 2016;16(7):751-8. doi:10.1080/14737140.2016.1192467 45. Perri F, Pacelli R, Della Vittoria Scarpati G, et al. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck. May 2015;37(5):763-70. doi:10.1002/hed.23837 46. Span PN, Bussink J. The Role of Hypoxia and the Immune System in Tumor Radioresistance. Cancers (Basel). Oct 14 2019;11(10)doi:10.3390/cancers11101555 47. Ganci F, Sacconi A, Manciocco V, et al. Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. 2015;doi:10.5772/60081 48. Dine J, Gordon R, Shames Y, et al. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J Oncol Nurs. Apr-Jun 2017;4(2):127-135. doi:10.4103/apjon.apjon_4_17 49. Fridman E, Na'ara S, Agarwal J, et al. The role of adjuvant treatment in early- stage oral cavity squamous cell carcinoma: An international collaborative study. Cancer. Jul 15 2018;124(14):2948-2955. doi:10.1002/cncr.31531 50. Cheng YJ, Tsai MH, Chiang CJ, et al. Adjuvant radiotherapy after curative surgery for oral cavity squamous cell carcinoma and treatment effect of timing and duration on outcome-A Taiwan Cancer Registry national database analysis. Cancer Med. Jul 2018;7(7):3073-3083. doi:10.1002/cam4.1611 51. Riemenschnitter CE, Morand GB, Schouten CS, et al. Need for adjuvant radiotherapy in oral cancer: depth of invasion rather than tumor diameter. Eur Arch Otorhinolaryngol. Jan 2023;280(1):339-346. doi:10.1007/s00405-022- 07561-x 52. Pu YM, Yang Y, Wang YJ, et al. Postoperative radiotherapy is dispensable for OSCC patients with micrometastases in lymph nodes. Virchows Arch. May 2018;472(5):797-805. doi:10.1007/s00428-018-2351-z 53. Hong KO, Oh KY, Shin WJ, et al. Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process. Hum Pathol. Oct 2018;80:123-129. doi:10.1016/j.humpath.2018.06.012 54. Alkhadar H, Macluskey M, White S, et al. Perineural invasion in oral squamous cell carcinoma: Incidence, prognostic impact and molecular insight. J Oral Pathol Med. Nov 2020;49(10):994-1003. doi:10.1111/jop.13069 55. Rylands J, Lowe D, Rogers SN. Outcomes by area of residence deprivation in a cohort of oral cancer patients: Survival, health-related quality of life, and place of death. Oral Oncol. Jan 2016;52:30-6. doi:10.1016/j.oraloncology.2015.10.017 56. Liu F, Chen F, Huang J, et al. Prospective study on factors affecting the prognosis of oral cancer in a Chinese population. Oncotarget. Jan 17 2017;8(3):4352-4359. doi:10.18632/oncotarget.13842 57. Gotz C, Drecoll E, Straub M, et al. Impact of HPV infection on oral squamous cell carcinoma. Oncotarget. Nov 22 2016;7(47):76704-76712. doi:10.18632/oncotarget.12501 58. Lyu X, Zhang M, Li G, et al. PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection. J Cancer. 2019;10(4):937-948. doi:10.7150/jca.27199 59. Schneider K, Jakobsen KK, Jensen JS, et al. Impact of p16-overexpression on overall and progression-free survival outcomes in oral cavity squamous cell carcinomas: A semi-national, population-based study. Oral Oncol. Dec 2020;111:105031. doi:10.1016/j.oraloncology.2020.105031 60. Lambert R, Sauvaget C, de Camargo Cancela M, et al. Epidemiology of cancer from the oral cavity and oropharynx. Eur J Gastroenterol Hepatol. Aug 2011;23(8):633-41. doi:10.1097/MEG.0b013e3283484795 61. Ramqvist T, Mints M, Tertipis N, et al. Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters. Oral Oncol. Dec 2015;51(12):1126-31. doi:10.1016/j.oraloncology.2015.09.007 62. Fakhry C, D'Souza G. Discussing the diagnosis of HPV-OSCC: common questions and answers. Oral Oncol. Sep 2013;49(9):863-871. doi:10.1016/j.oraloncology.2013.06.002 63. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T- cell apoptosis: a potential mechanism of immune evasion. Nat Med. Aug 2002;8(8):793-800. doi:10.1038/nm730 64. Lin NC, Hsu JT, Tsai KY. Difference between Female and Male Patients with Oral Squamous Cell Carcinoma: A Single-Center Retrospective Study in Taiwan. Int J Environ Res Public Health. Jun 4 2020;17(11)doi:10.3390/ijerph17113978 65. Satgunaseelan L, Gupta R, Madore J, et al. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology. Oct 2016;48(6):574-80. doi:10.1016/j.pathol.2016.07.003 66. Maruse Y, Kawano S, Jinno T, et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. Jul 2018;47(7):836-845. doi:10.1016/j.ijom.2018.01.004 67. Troeltzsch M, Woodlock T, Pianka A, et al. Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. J Oral Maxillofac Surg. May 2017;75(5):969-977. doi:10.1016/j.joms.2016.11.006 68. Kouketsu A, Sato I, Oikawa M, et al. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. J Craniomaxillofac Surg. Jan 2019;47(1):33-40. doi:10.1016/j.jcms.2017.04.013 69. Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget. Aug 28 2015;6(25):20902-20. doi:10.18632/oncotarget.3939 70. Lin YM, Sung WW, Hsieh MJ, et al. High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. PLoS One. 2015;10(11):e0142656. doi:10.1371/journal.pone.0142656 71. Straub M, Drecoll E, Pfarr N, et al. CD274/PD-L1 gene amplification and PD- L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget. Mar 15 2016;7(11):12024-34. doi:10.18632/oncotarget.7593 72. Chen T-C, Wu C-T, Wang C-P, et al. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof. Oral Oncology. 2015;51(11):1004- 1010. doi:10.1016/j.oraloncology.2015.08.011 73. Ahn H, Yang JM, Kim H, et al. Clinicopathologic implications of the miR- 197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget. Sep 12 2017;8(39):66178-66194. doi:10.18632/oncotarget.19842 74. Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. Jan 2017;50(1):41-48. doi:10.3892/ijo.2016.3785 75. Mattox AK, Lee J, Westra WH, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs. Cancer Res. Nov 15 2017;77(22):6365-6374. doi:10.1158/0008-5472.CAN-16-3453 76. Kogashiwa Y, Yasuda M, Sakurai H, et al. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Res. Mar 2017;37(3):1417-1424. doi:10.21873/anticanres.11465 77. Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M. Immunohistochemical Analysis of Foxp3(+), CD4(+), CD8(+) Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma. Pathol Oncol Res. Jul 2018;24(3):497-505. doi:10.1007/s12253-017-0270-y 78. De Vicente JC, Rodriguez-Santamarta T, Rodrigo JP, et al. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. Mar 2019;28(3):546-554. doi:10.1158/1055-9965.EPI-18-0779 79. Weber M, Wehrhan F, Baran C, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. Dec 22 2017;8(68):112584-112597. doi:10.18632/oncotarget.22576 80. He J, Chen XF, Xu MG, et al. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. Arch Oral Biol. Jun 2020;114:104717. doi:10.1016/j.archoralbio.2020.104717 81. Boustani J, Grapin M, Laurent PA, et al. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers (Basel). Jun 20 2019;11(6)doi:10.3390/cancers11060860 82. Nguyễn Chấn Hùng, Phạm Xuân Dũng, Đặng Huy Quốc Thịnh. Ức chế chốt kiểm trong liệu pháp miễn dịch ung thư. Tạp chí Ung thư học Việt Nam. 2018;4:i-v. 83. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. https://www.fda.gov/drugs/resources-information- approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and- neck-squamous-cell-carcinoma 84. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. Nov 23 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7 85. Punekar SR, Shum E, Grello CM, et al. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol. 2022;12:877594. doi:10.3389/fonc.2022.877594 86. Fasano M, Corte CMD, Liello RD, et al. Immunotherapy for head and neck cancer: Present and future. Crit Rev Oncol Hematol. Jun 2022;174:103679. doi:10.1016/j.critrevonc.2022.103679 87. De Bree R, Senft A, Coca-Pelaz A, et al. Detection of Distant Metastases in Head and Neck Cancer: Changing Landscape. Adv Ther. Feb 2018;35(2):161-172. doi:10.1007/s12325-018-0662-8 88. Kikuchi M, Harada H, Asato R, et al. Lingual Lymph Node Metastases as a Prognostic Factor in Oral Squamous Cell Carcinoma-A Retrospective Multicenter Study. Medicina (Kaunas). Apr 12 2021;57(4)doi:10.3390/medicina57040374 89. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;(6):1471-1474. doi:10.1245/s10434-010-0985-. Ann Surg Oncol 2010;17(6)doi:doi:10.1245/s10434-010-0985-4 90. Kademani D, Bell RB, Bagheri S, et al. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg. Nov 2005;63(11):1599-605. doi:10.1016/j.joms.2005.07.011 91. Yoshida S, Nagatsuka H, Nakano K, et al. Significance of PD-L1 Expression in Tongue Cancer Development. Int J Med Sci. 2018;15(14):1723-1730. doi:10.7150/ijms.27860 92. Cohen EEW BR, Bifulco CB, et al. . The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7(1):184. doi:10.1186/s40425-019-0662-5 93. Huang XQ, Chen X, Xie XX, et al. Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7(4):1651-66. 94. Weckx A, Riekert M, Grandoch A, et al. Time to recurrence and patient survival in recurrent oral squamous cell carcinoma. Oral Oncol. Jul 2019;94:8-13. doi:10.1016/j.oraloncology.2019.05.002 95. Nguyễn Văn Tuấn. Phân tích dữ liệu với R. NXB Tổng hợp TP HCM. 2014;Phân tích sống còn:261-283. 96. Jawad H, Ashaari SS, O'Shea R, et al. Prognostic performance of TNM8 staging rules in oral cavity squamous cell carcinoma. Oral Oncol. Dec 2020;111:105021. doi:10.1016/j.oraloncology.2020.105021 97. Tirelli G, Gatto A, Boscolo Nata F, et al. Prognosis of oral cancer: a comparison of the staging systems given in the 7th and 8th editions of the American Joint Committee on Cancer Staging Manual. Br J Oral Maxillofac Surg. Jan 2018;56(1):8-13. doi:10.1016/j.bjoms.2017.11.009 98. Nguyễn Thị Nguyệt Ánh, Nguyễn Chấn Hùng, Nguyễn Thị Hồng, et al. Biểu hiện keratin 4 trong biểu mô bình thường và ung thư tế bào gai niêm mạc miệng. Tạp chí Ung thư học Việt Nam. 2017;20 (5) 99. Ferreira AK, Carvalho SH, Granville-Garcia AF, et al. Survival and prognostic factors in patients with oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. May 1 2021;26(3):e387-e392. doi:10.4317/medoral.24242 100. Rikardsen OG, Bjerkli IH, Uhlin-Hansen L, et al. Clinicopathological characteristics of oral squamous cell carcinoma in Northern Norway: a retrospective study. BMC Oral Health. Aug 18 2014;14:103. doi:10.1186/1472- 6831-14-103 101. Kruse AL, Bredell M, Gratz KW. Oral cancer in men and women: are there differences? Oral Maxillofac Surg. Mar 2011;15(1):51-5. doi:10.1007/s10006- 010-0253-6 102. Falaki F, Dalirsani Z, Pakfetrat A, et al. Clinical and histopathological analysis of oral squamous cell carcinoma of young patients in Mashhad, Iran: a retrospective study and review of literature. Med Oral Patol Oral Cir Bucal. Jul 1 2011;16(4):e473-7. doi:10.4317/medoral.16.e473 103. Patel SG, Amit M, Yen TC, et al. Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research. British Journal of Cancer. 2013;109(8):2087-2095. doi:10.1038/bjc.2013.570 104. LeHew CW, Epstein JB, Kaste LM, et al. Assessing oral cancer early detection: clarifying dentists' practices. J Public Health Dent. Spring 2010;70(2):93-100. doi:10.1111/j.1752-7325.2009.00148.x 105. Brocklehurst PR, Baker SR, Speight PM. A qualitative study examining the experience of primary care dentists in the detection and management of potentially malignant lesions. 1. Factors influencing detection and the decision to refer. Br Dent J. Jan 23 2010;208(2):E3; discussion 72-3. doi:10.1038/sj.bdj.2010.54 106. Mavedatnia D, Cuddy K, Klieb H, et al. Oral cancer screening knowledge and practices among dental professionals at the University of Toronto. BMC Oral Health. May 31 2023;23(1):343. doi:10.1186/s12903-023-03062-3 107. Zanoni DK, Montero PH, Migliacci JC, et al. Survival outcomes after treatment of cancer of the oral cavity (1985-2015). Oral Oncol. Mar 2019;90:115-121. doi:10.1016/j.oraloncology.2019.02.001 108. Siriwardena BS, Rasnayaka RM, Masood Y, et al. Predictive model of oral cancer metastasis for different cancer sites and age groups. J Investig Clin Dent. May 2016;7(2):127-31. doi:10.1111/jicd.12145 109. Lee DS, Ramirez RJ, Lee JJ, et al. Survival of Young Versus Old Patients With Oral Cavity Squamous Cell Carcinoma: A Meta-Analysis. Laryngoscope. Jun 2021;131(6):1310-1319. doi:10.1002/lary.29260 110. Pires FR, Ramos AB, Oliveira JB, et al. Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. J Appl Oral Sci. Sep-Oct 2013;21(5):460-7. doi:10.1590/1679-775720130317 111. Hoda N, Bc R, Ghosh S, et al. Cervical lymph node metastasis in squamous cell carcinoma of the buccal mucosa: a retrospective study on pattern of involvement and clinical analysis. Med Oral Patol Oral Cir Bucal. Jan 1 2021;26(1):e84-e89. doi:10.4317/medoral.24016 112. Kreppel M, Nazarli P, Grandoch A, et al. Clinical and histopathological staging in oral squamous cell carcinoma - Comparison of the prognostic significance. Oral Oncol. Sep 2016;60:68-73. doi:10.1016/j.oraloncology.2016.07.004 113. Xu B, Salama AM, Valero C, et al. The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: a comparative study. Virchows Arch. Sep 2021;479(3):597-606. doi:10.1007/s00428-021-03063-z 114. Cariati P, Martinez Sahuquillo Rico A, Ferrari L, et al. Impact of histological tumor grade on the behavior and prognosis of squamous cell carcinoma of the oral cavity. J Stomatol Oral Maxillofac Surg. Nov 2022;123(6):e808-e813. doi:10.1016/j.jormas.2022.07.005 115. Okada Y, Mataga I, Katagiri M, et al. An analysis of cervical lymph nodes metastasis in oral squamous cell carcinoma. Relationship between grade of histopathological malignancy and lymph nodes metastasis. Int J Oral Maxillofac Surg. Jun 2003;32(3):284-8. doi:10.1054/ijom.2002.0303 116. Mai Trọng Khoa, Nguyễn Xuân Kử. Một số tiến bộ về kỹ thuật xạ trị ung thư và ứng dụng trong lâm sàng. NXB Y học, Hà Nội; 2012. 117. Schulz D, Streller M, Piendl G, et al. Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma. Carcinogenesis. Jul 14 2020;41(7):984-992. doi:10.1093/carcin/bgz177 118. Knochelmann HM, Horton JD, Liu S, et al. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. Oct 19 2021;2(10):100426. doi:10.1016/j.xcrm.2021.100426 119. Strati A, Koutsodontis G, Papaxoinis G, et al. Prognostic significance of PD- L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. Aug 1 2017;28(8):1923-1933. doi:10.1093/annonc/mdx206 120. Cho YA YH, Lee JI, et al. . Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. . Oral Oncol 2011;47(12):1148-1153. doi:10.1016/j.oraloncology.2011.08.007 121. Koppel C SH, Zielinski D, et al. . Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol 2018;31(11):1630-1644. doi:10.1038/s41379-018-0071-1 122. Cheng Y, Song Z, Chen J, et al. Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods. Heliyon. Feb 29 2024;10(4):e25895. doi:10.1016/j.heliyon.2024.e25895 123. Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA oncology. 2020;6(10):1563-1570. 124. Greeshma L, Joseph AP, Sivakumar T, et al. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Scientific Reports. 2023;13(1):21698. 125. Steen S, Semmelmayer K, Flechtenmacher C, et al. Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma. Int J Mol Sci. Nov 16 2023;24(22)doi:10.3390/ijms242216386 126. Hu C, Tian S, Lin L, et al. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Oral Oncology. 2020;102:104560. 127. Soopanit T, Laokulrath N, Chayopasakul V, et al. Prognostic value and clinicopathological status of PD‐L1 expression and CD8+ TILs in oral squamous cell cancer patients with or without traditional risk factors. Head & Neck. 2023;45(4):1017-1025. 128. Owadally W, Hurt C, Timmins H, et al. PATHOS: a phase II/III trial of risk- stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer. Aug 27 2015;15:602. doi:10.1186/s12885-015-1598-x 129. Li CX, Tan XR, Wei W, et al. A radiobiological perspective on radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma. Rep Pract Oncol Radiother. 2023;28(6):809-822. doi:10.5603/rpor.99355 130. Kernohan MD, Clark JR, Gao K, et al. Predicting the prognosis of oral squamous cell carcinoma after first recurrence. Arch Otolaryngol Head Neck Surg. Dec 2010;136(12):1235-9. doi:10.1001/archoto.2010.214 131. Kim MG, Choi YS, Youn SM, et al. Treatment outcomes and prognostic factors in oral tongue cancer: a 20-year retrospective study at the National Cancer Center, South Korea. J Korean Assoc Oral Maxillofac Surg. Aug 31 2022;48(4):192-200. doi:10.5125/jkaoms.2022.48.4.192 132. Lim YJ, Kong M. Population-based comparative survival analysis of surgery with or without adjuvant radiotherapy and non-operative primary radiotherapy in patients with early-stage oral tongue squamous cell carcinoma. Plos one. 2021;16(11):e0259384. 133. Silva LABd, Lopes MLDdS, Sá MC, et al. Histopathologic grading and its relationship with outcome in oral tongue squamous cell carcinoma. Journal of Oral Pathology & Medicine. 2021;50(2):183-190. 134. Amit M, Yen TC, Liao CT, et al. Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. Cancer. Dec 15 2013;119(24):4242-8. doi:10.1002/cncr.28357 135. Kim MJ, Ahn KM. Prognostic factors of oral squamous cell carcinoma: the importance of recurrence and pTNM stage. Maxillofac Plast Reconstr Surg. Mar 4 2024;46(1):8. doi:10.1186/s40902-024-00410-3 136. Amit M, Tam S, Takahashi H, et al. Prognostic performance of the American Joint Committee on Cancer 8th edition of the TNM staging system in patients with early oral tongue cancer. Head Neck. May 2019;41(5):1270-1276. doi:10.1002/hed.25553 137. Zhang H, Dziegielewski PT, Nguyen TJ, et al. The effects of geography on survival in patients with oral cavity squamous cell carcinoma. Oral Oncology. 2015;51(6):578-585. 138. Vuity D, McMahon J, Takhiuddin S, et al. Is the 8th edition of the Union for International Cancer Control staging of oral cancer good enough? Br J Oral Maxillofac Surg. May 2018;56(4):272-277. doi:10.1016/j.bjoms.2018.01.017 139. Justesen MM, Stampe H, Jakobsen KK, et al. Impact of tumor subsite on survival outcomes in oral squamous cell carcinoma: A retrospective cohort study from 2000 to 2019. Oral Oncology. 2024;149:106684. 140. Lee DS, Ramirez RJ, Lee JJ, et al. Survival of young versus old patients with oral cavity squamous cell carcinoma: a meta‐analysis. The Laryngoscope. 2021;131(6):1310-1319. 141. Hilly O, Shkedy Y, Hod R, et al. Carcinoma of the oral tongue in patients younger than 30 years: comparison with patients older than 60 years. Oral Oncol. Oct 2013;49(10):987-90. doi:10.1016/j.oraloncology.2013.07.005 142. Soudry E, Preis M, Hod R, et al. Squamous cell carcinoma of the oral tongue in patients younger than 30 years: clinicopathologic features and outcome. Clin Otolaryngol. Aug 2010;35(4):307-12. doi:10.1111/j.1749-4486.2010.02164.x 143. Santos-Silva AR, Ribeiro AC, Soubhia AM, et al. High incidences of DNA ploidy abnormalities in tongue squamous cell carcinoma of young patients: an international collaborative study. Histopathology. Jun 2011;58(7):1127-35. doi:10.1111/j.1365-2559.2011.03863.x 144. Ghantous Y, Nashef A, Sidransky D, et al. Clinical and Prognostic Significance of the Eighth Edition Oral Cancer Staging System. Cancers (Basel). Sep 23 2022;14(19)doi:10.3390/cancers14194632 145. Shinohara S, Kikuchi M, Harada H, et al. Clinicopathological Characteristics and Survival Outcomes of Patients with Buccal Squamous Cell Carcinoma: Results of a Multi-Institutional Study. Medicina (Kaunas). Dec 13 2021;57(12)doi:10.3390/medicina57121361 146. Choi N, Noh Y, Lee EK, et al. Discrepancy between cTNM and pTNM staging of oral cavity cancers and its prognostic significance. J Surg Oncol. Jun 2017;115(8):1011-1018. doi:10.1002/jso.24606 147. Erazo-Puentes MC, Sanchez-Torres A, Aguirre-Urizar JM, et al. Has the 8th American joint committee on cancer TNM staging improved prognostic performance in oral cancer? A systematic review. Med Oral Patol Oral Cir Bucal. Mar 1 2024;29(2):e163-e171. doi:10.4317/medoral.25983 148. Liao L-J, Lo W-C, Hsu W-L, et al. Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck—a meta- analysis comparing different imaging modalities. BMC cancer. 2012;12:1-7. 149. Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node‐positive head and neck squamous cell carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2008;112(3):535-543. 150. Li M, Xuan G, Gu H, et al. Survival benefit associated with postoperative PET-CT before adjuvant radiotherapy or chemoradiotherapy in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg. Nov 2022;51(11):1382- 1388. doi:10.1016/j.ijom.2022.03.001 151. Gartagani Z, Doumas S, Kyriakopoulou A, et al. Lymph node ratio as a prognostic factor in neck dissection in oral cancer patients: a systematic review and meta-analysis. Cancers. 2022;14(18):4456. 152. Almangush A, Pirinen M, Youssef O, et al. Risk stratification in oral squamous cell carcinoma using staging of the eighth American Joint Committee on Cancer: Systematic review and meta‐analysis. Head & Neck. 2020;42(10):3002-3017. 153. Lin N-C, Hsu J-T, Tsai K-Y. Survival and clinicopathological characteristics of different histological grades of oral cavity squamous cell carcinoma: A single- center retrospective study. PLoS One. 2020;15(8):e0238103. 154. Ur Rahaman SM, Ahmed Mujib B. Histopathological correlation of oral squamous cell carcinoma among younger and older patients. J Oral Maxillofac Pathol. May 2014;18(2):183-8. doi:10.4103/0973-029X.140734 155. Wagner VP, Webber LP, Curra M, et al. Bryne's grading system predicts poor disease-specific survival of oral squamous cell carcinoma: a comparative study among different histologic grading systems. Oral Surg Oral Med Oral Pathol Oral Radiol. Jun 2017;123(6):688-696. doi:10.1016/j.oooo.2017.02.012